Publications

Found 4 results
Filters: Author is A.A.S. Reis  [Clear All Filters]
2010
A. A. S. Reis, Silva, D. M., Curado, M. P., and da Cruz, A. D., Involvement of CYP1A1, GST, 72TP53 polymorphisms in the pathogenesis of thyroid nodules, vol. 9, pp. 2222-2229, 2010.
Agundez JA (2004). Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab. 5: 211-224. http://dx.doi.org/10.2174/1389200043335621 PMid:15180491   Almeida PS, Manoel WJ, Reis AA, Silva ER, et al. (2008). TP53 codon 72 polymorphism in adult soft tissue sarcomas. Genet. Mol. Res. 7: 1344-1352. http://dx.doi.org/10.4238/vol7-4gmr497 PMid:19065769   Aral C, Çaglayan S, Ösizik G, Massoumilary S, et al. (2007). The association of P53 codon 72 polymorphism with thyroid cancer in Turkish patients. Marmara Med. J. 20: 1-5.   Boltze C, Roessner A, Landt O, Szibor R, et al. (2002). Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int. J. Oncol. 21: 1151-1154. PMid:12370767   Bozina N, Bradamante V and Lovric M (2009). Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh. Hig. Rada Toksikol. 60: 217-242. http://dx.doi.org/10.2478/10004-1254-60-2009-1885 PMid:19581216   Bufalo NE, Leite JL, Guilhen AC, Morari EC, et al. (2006). Smoking and susceptibility to thyroid cancer: an inverse association with CYP1A1 allelic variants. Endocr. Relat. Cancer 13: 1185-1193. http://dx.doi.org/10.1677/ERC-06-0002 PMid:17158763   Chen RH, Chang CT, Wang TY, Huang WL, et al. (2008). p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases. J. Clin. Lab. Anal. 22: 321-326. http://dx.doi.org/10.1002/jcla.20249 PMid:18803266   Dean DS and Gharib H (2008). Epidemiology of thyroid nodules. Best Pract. Res. Clin. Endocrinol. Metab. 22: 901-911. http://dx.doi.org/10.1016/j.beem.2008.09.019 PMid:19041821   Gaspar J, Rodrigues S, Gil OM, Manita I, et al. (2004). Combined effects of glutathione S-transferase polymorphisms and thyroid cancer risk. Cancer Genet. Cytogenet. 151: 60-67. http://dx.doi.org/10.1016/j.cancergencyto.2003.09.018 PMid:15120911   Gonçalves AJ, Carvalho LH, Serdeira K, Nakai MY, et al. (2007). Comparative analysis of the prevalence of the glutathione S-transferase (GST) system in malignant and benign thyroid tumor cells. São Paulo Med. J. 125: 289-291. http://dx.doi.org/10.1590/S1516-31802007000500008 PMid:18094897   Hegedüs L (2004). Clinical practice. The thyroid nodule. N. Engl. J. Med. 351: 1764-1771. http://dx.doi.org/10.1056/NEJMcp031436 PMid:15496625   Hegedüs L, Bonnema SJ and Bennedbaek FN (2003). Management of simple nodular goiter: current status and future perspectives. Endocr. Rev. 24: 102-132. http://dx.doi.org/10.1210/er.2002-0016 PMid:12588812   Hernández A, Céspedes W, Xamena N, Surrallés J, et al. (2003). Glutathione S-transferase polymorphisms in thyroid cancer patients. Cancer Lett. 190: 37-44. http://dx.doi.org/10.1016/S0304-3835(02)00580-3   Ho T, Zhao C, Zheng R, Liu Z, et al. (2006). Glutathione S-transferase polymorphisms and risk of differentiated thyroid carcinomas: a case-control analysis. Arch. Otolaryngol. Head Neck Surg. 132: 756-761. http://dx.doi.org/10.1001/archotol.132.7.756 PMid:16847185   Lemos MC, Coutinho E, Gomes L, Carrilho F, et al. (2008). Combined GSTM1 and GSTT1 null genotypes are associated with a lower risk of papillary thyroid cancer. J. Endocrinol. Invest. 31: 542-545. PMid:18591888   Masson LF, Sharp L, Cotton SC and Little J (2005). Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: A HuGE review. Am. J. Epidemiol. 161: 901-915. http://dx.doi.org/10.1093/aje/kwi121 PMid:15870154   Mazzaferri EL (2006). Managing small thyroid cancer. JAMA 295: 2179-2182. http://dx.doi.org/10.1007/b136179   Morari EC, Leite JL, Granja F, da Assumpcao LV, et al. (2002). The null genotype of glutathione s-transferase M1 and T1 locus increases the risk for thyroid cancer. Cancer Epidemiol. Biomarkers Prev. 11: 1485-1488. PMid:12433731   Nebert DW, McKinnon RA and Puga A (1996). Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 15: 273-280. http://dx.doi.org/10.1089/dna.1996.15.273 PMid:8639263   Rossini A, Rapozo DC, Amorim LM, Macedo JM, et al. (2002). Frequencies of GSTM1, GSTT1, and GSTP1 polymorphisms in a Brazilian population. Genet. Mol. Res. 1: 233-240. PMid:14963830   Siraj AK, Ibrahim M, Al-Rasheed M, Abubaker J, et al. (2008). Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. B.M.C. Med. Genet. 9: 61. http://dx.doi.org/10.1186/1471-2350-9-61 PMid:18601742 PMCid:2492854   Song N, Tan W, Xing D and Lin D (2001). CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 22: 11-16. http://dx.doi.org/10.1093/carcin/22.1.11 PMid:11159735   Sourvinos G, Rizos E and Spandidos DA (2001). p53 Codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncol. 37: 572-578. http://dx.doi.org/10.1016/S1368-8375(00)00139-1   Stankov K, Landi S, Gioia-Patricola L, Bonora E, et al. (2006). GSTT1 and M1 polymorphisms in Hürthle thyroid cancer patients. Cancer Lett. 240: 76-82. http://dx.doi.org/10.1016/j.canlet.2005.08.017 PMid:16427734   Sweeney C, Farrow DC, Schwartz SM, Eaton DL, et al. (2000). Glutathione S-transferase M1, T1, and P1 polymorphisms as risk factors for renal cell carcinoma: a case-control study. Cancer Epidemiol. Biomarkers Prev. 9: 449-454. PMid:10794492